Evidence map›Paper›PMID 42096132›Full record

ArticleEuropean journal of epidemiology2026

Prevalence, characteristics, and projection of long-term childhood cancer survivors in Sweden.

Elena Extrand, Emerald G Heiland, Genevieve Allen, Mia Giertz, Hanna Mogensen, Hannah L Brooke

Abstract read
In one paragraph

Article in European journal of epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Elena ExtrandMedical Epidemiology, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Emerald G HeilandMedical Epidemiology, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Genevieve AllenMedical Epidemiology, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Mia GiertzDepartment of Women and Children's Health, Uppsala University, Uppsala, Sweden.
Hanna Mogensen *Department of Immunology, Genetics and Pathology, Cancer Precision Medicine, Uppsala University, Uppsala, Sweden.
Hannah L Brooke *Medical Epidemiology, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. hannah.brooke@uu.se.ORCID http://orcid.org/0000-0002-7085-1551

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Population-level descriptions of long-term childhood cancer survivors are fundamental to survivorship care and research but seldom available. Accordingly, we aimed to describe long-term childhood cancer survivors at the population-level and project future prevalence. In this register-based study we calculated the absolute number and prevalence proportions of all individuals diagnosed with a childhood cancer (aged 0-14 years, 1958-2018) in Sweden who survived ≥ 5 years post-diagnosis and were alive and residing in Sweden on December 31st, 2023. We also described the clinical and sociodemographic characteristics of this population and presented the observed prevalence over time (1990-2023) and projected prevalence under different mortality assumptions (2024-2040). On December 31st, 2023, there were 8645 long-term childhood cancer survivors in Sweden, equivalent to nearly 1 in 1000 inhabitants (921 persons per million). Leukemias (28.3%) and central nervous system tumors (27.0%) were the most common childhood cancer diagnoses, although the distribution of cancer type varied by attained age. Disease burden in the preceding five years was heterogeneous: approximately 25-30% of the survivors had no recent diagnoses or prescriptions, while a similar proportion experienced substantial morbidity. Most adult survivors were employed (72.0%) and relatively few received sickness benefits (9.7%). From 1990 to 2023, the long-term survivor population tripled in size. Projected mean annual growth was between 1.6% and 2.2%, with the population increasing to approximately 11,400 - 12,600 individuals by 2040. As this heterogeneous population continues growing, our comprehensive description can help plan survivorship care and provide a benchmark for prevalence estimates in settings with less complete data.

Indexed as

Cancer SurvivorsNeoplasmsAdolescentAdultChildChild, PreschoolFemaleHumansInfantInfant, NewbornMalePrevalenceRegistriesSwedenCancer survivorsChildEpidemiologyNeoplasmsPediatricsPrevalence

Identifiers

PMID42096132
PMCPMC13423994

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.